Astellas Pharma vs Chugai Pharmaceutical Co.: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Astellas Pharma Inc. (4503.JP)

Q3 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

August 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Latest15 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Chugai Pharmaceutical Co., Ltd. (4519.JP)

Q3 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

August 202624 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.

Latest24 Jul – 5 Oct 2026

▲2▼2

Chugai's profit rises but obesity drug setback and unchanged guidance weigh

First-half profit jumps 19% Chugai's first-half net profit rose 19% to 231.7 billion yen, with stable margins. This shows the core business is growing steadily, which supports the stock's value over time.
It shows the company's underlying earnings strength, a key reason investors hold the stock.
Full-year guidance left unchanged Despite higher first-half profit, Chugai kept its full-year forecast unchanged. Investors saw this as a sign that future growth may be limited, and the stock fell about 3% on the news.
It explains why the stock dropped even though profits rose, a key driver of sentiment.
Roche halts obesity drug development Roche stopped developing the obesity drug emugrobart (GYM329) after Phase II data showed weight loss was unlikely to meet targets. Chugai shares fell to a year-to-date low as investors worried about pipeline setbacks.
It is the main negative event of the period, directly hitting the stock price.
Chugai regains rights, plans new use Chugai got full rights back to emugrobart and will restart development for spinal muscular atrophy, a different disease. This could turn a setback into a new opportunity, though analysts see it as only a small positive for now.
It shows a potential recovery path after the negative news, balancing the picture.